Publications

Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports  (2022)

Authors:
Quinzii, Alberto; Zecchetto, Camilla; Casalino, Simona; Gaule, Marina; Pesoni, Camilla; Merz, Valeria; Contarelli, Serena; Pietrobono, Silvia; Benhadji, Karim A; Melisi, Davide
Title:
Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports
Year:
2022
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Referee:
No
Name of journal:
Clinical Drug Investigation
ISSN of journal:
1173-2563
N° Volume:
42
Number or Folder:
8
Page numbers:
697-701
Keyword:
Gastric cancer
Short description of contents:
Gastric cancer is the fifth most frequently diagnosed cancer worldwide and the third leading cause of cancer-related deaths [1]. Nearly two-thirds of newly diagnosed gastric cancer patients in Western countries present with advanced disease and are therefore being offered systemic treatments.
Product ID:
132337
Handle IRIS:
11562/1087016
Last Modified:
October 17, 2024
Bibliographic citation:
Quinzii, Alberto; Zecchetto, Camilla; Casalino, Simona; Gaule, Marina; Pesoni, Camilla; Merz, Valeria; Contarelli, Serena; Pietrobono, Silvia; Benhadji, Karim A; Melisi, Davide, Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports «Clinical Drug Investigation» , vol. 42 , n. 82022pp. 697-701

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<back

Activities

Research facilities

Share